2005
DOI: 10.1179/acb.2005.014
|View full text |Cite
|
Sign up to set email alerts
|

EVALUATION OF THE STRATUS®CS FLUOROMETER FOR THE DETERMINATION OF PLASMA MYOGLOBIN

Abstract: Circulating myoglobin is recognized as an early and sensitive marker of acute coronary diseases. Long turnaround time of myoglobin assays jeopardize their clinical utility. We evaluated the analytical performance of the Stratus CS fluorometric enzyme immunoassay based on dendrimer technology, and claimed to achieve a fast and reliable determination of plasma myoglobin concentrations. Precision complied with the recommended analytical performance criteria. Method comparison and recovery experiments indicated, t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2008
2008
2012
2012

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…They have, for example, been shown to be effective drug delivery vehicles for oligonucleotides, [36] methotrexate, [37] folic acid, [38] taxol, [38] methylprednisolone, [39] doxorubicin [40] and boron-rich compounds for boron neutron capture therapy (BNCT) [41][42][43] and are even the basis for approved pharmaceuticals such as the microbicide Vivagel [44] and the diagnostic cardiac marker Stratus. [45] Thus, well-characterised dendritic substances containing a high number of fluorescent dyes and a functional group for selective coupling to a carrier molecule should be advantageous to the introduction of a high number of dyes concentrated at one position of the compound to be labelled. Therefore, high dye concentrations that produce strong fluorescence signals should become assessable for improved fluorescence labelling.…”
Section: Introductionmentioning
confidence: 99%
“…They have, for example, been shown to be effective drug delivery vehicles for oligonucleotides, [36] methotrexate, [37] folic acid, [38] taxol, [38] methylprednisolone, [39] doxorubicin [40] and boron-rich compounds for boron neutron capture therapy (BNCT) [41][42][43] and are even the basis for approved pharmaceuticals such as the microbicide Vivagel [44] and the diagnostic cardiac marker Stratus. [45] Thus, well-characterised dendritic substances containing a high number of fluorescent dyes and a functional group for selective coupling to a carrier molecule should be advantageous to the introduction of a high number of dyes concentrated at one position of the compound to be labelled. Therefore, high dye concentrations that produce strong fluorescence signals should become assessable for improved fluorescence labelling.…”
Section: Introductionmentioning
confidence: 99%